Welcome members and clients of OMMP PIF. Due to increased costs, our website has moved to this server, Thanks go to our Friend and colleague, Wired57, for making this possible. If you have any questions or concerns, please start a new topic in 
Thank you 
07-11-2012, 12:07 PM
Amyotrophic Lateral Sclerosis (ALS)
http://www.youtube.com/watch?v=d6nX8ecP5II
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs Disease, is a fatal neurodegenerative disorder that is characterized by the selective loss of motor neurons in the spinal cord, brain stem, and motor cortex. An estimated 30,000 Americans are living with ALS, which often arises spontaneously and afflicts otherwise healthy adults. More than half of ALS patients die within 2.5 years following the onset of symptoms.
A review of the scientific literature reveals an absence of clinical trials investigating the use of cannabinoids for ALS treatment. However, recent preclinical findings indicate that cannabinoids can delay ALS progression, lending support to anecdotal reports by patients that cannabinoids may be efficacious in moderating the diseases development and in alleviating certain ALS-related symptoms such as pain, appetite loss, depression and drooling.[1]
Writing in the March 2004 issue of the journal Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, investigators at the California Pacific Medical Center in San Francisco reported that the administration of THC both before and after the onset of ALS symptoms staved disease progression and prolonged survival in animals compared to untreated controls.[2]
Additional trials in animal models of ALS have shown that the administration of other naturally occurring and synthetic cannabinoids can also moderate ALS progression, but not necessarily impact survival.[3-4] One recent study demonstrated that blocking the CB1 cannabinoid receptor did extend life span in an ALS mouse model, suggesting that cannabinoids beneficial effects on ALS may be mediated by non-CB1 receptor mechanisms.[5]
Preclinical data has also shown that cannabinoids are neuroprotective against oxidative damage both in vitro[6] and in animals.[7] Cannabinoids neuroprotective action may be able to play a role in moderating ALS, which is characterized by excessive glutamate activity in the spinal cord.[8] At least one cannabinoid, delta-9-THC, has been shown to protect cultured mouse spinal neurons against excitotoxicity.[9]
As a result, some experts now recommend that marijuana be considered in the pharmacological management of ALS,[10] and they believe that further investigation into the usefulness of marijuana and synthetic cannabinoid receptor agonists is warranted.[11]
REFERENCES
[1] Amtmann et al. 2004. Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 21: 95-104.
[2] Raman et al. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.
[3] Weydt et al. 2005. Cannabinol delays symptom onset in SOD1 transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 6: 182-184.
[4] Bilsland et al. 2006. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. The FASEB Journal 20: 1003-1005.
[5] Ibid.
[6] Raman et al. 2004. op.cit.
[7] Hampson et al. 1998. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268-8273.
[8] Carter and Weydt. 2002. Cannabis: Old medicine with new promise for neurological disorders. Current Opinion in Investigational Drugs 3: 437-440.
[9] Abood et al. 2001. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Letters 309: 197-201.
[10] Carter and Rosen. 2001. Marijuana in the management of amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 18: 264-70.
[11] Carter et al. 2003. Drug therapy for amyotrophic lateral sclerosis: Where are we now? The Investigational Drugs Journal 6: 147-153.
source: [/url][url=?Group_ID=7004%5B/url%5D]http://www.norml.org...m?Group_ID=7004
Why choose Mayo Clinic
At Mayo Clinic, doctors who have training in neuromuscular conditions (neurologists) and several other specialists work closely as a team to care for people who have this condition. Doctors offer treatment and continuing care that can address your medical needs and improve your quality of life. Mayo Clinic offers you and your family many resources for support, information and education.
Mayo Clinic in Rochester, Minn., is ranked among the Best Hospitals for neurology and neurosurgery by U.S. News & World Report.
Read more about Lou Gehrig's disease at MayoClinic.com.
http://www.youtube.com/watch?v=d6nX8ecP5II
Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrigs Disease, is a fatal neurodegenerative disorder that is characterized by the selective loss of motor neurons in the spinal cord, brain stem, and motor cortex. An estimated 30,000 Americans are living with ALS, which often arises spontaneously and afflicts otherwise healthy adults. More than half of ALS patients die within 2.5 years following the onset of symptoms.
A review of the scientific literature reveals an absence of clinical trials investigating the use of cannabinoids for ALS treatment. However, recent preclinical findings indicate that cannabinoids can delay ALS progression, lending support to anecdotal reports by patients that cannabinoids may be efficacious in moderating the diseases development and in alleviating certain ALS-related symptoms such as pain, appetite loss, depression and drooling.[1]
Writing in the March 2004 issue of the journal Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders, investigators at the California Pacific Medical Center in San Francisco reported that the administration of THC both before and after the onset of ALS symptoms staved disease progression and prolonged survival in animals compared to untreated controls.[2]
Additional trials in animal models of ALS have shown that the administration of other naturally occurring and synthetic cannabinoids can also moderate ALS progression, but not necessarily impact survival.[3-4] One recent study demonstrated that blocking the CB1 cannabinoid receptor did extend life span in an ALS mouse model, suggesting that cannabinoids beneficial effects on ALS may be mediated by non-CB1 receptor mechanisms.[5]
Preclinical data has also shown that cannabinoids are neuroprotective against oxidative damage both in vitro[6] and in animals.[7] Cannabinoids neuroprotective action may be able to play a role in moderating ALS, which is characterized by excessive glutamate activity in the spinal cord.[8] At least one cannabinoid, delta-9-THC, has been shown to protect cultured mouse spinal neurons against excitotoxicity.[9]
As a result, some experts now recommend that marijuana be considered in the pharmacological management of ALS,[10] and they believe that further investigation into the usefulness of marijuana and synthetic cannabinoid receptor agonists is warranted.[11]
REFERENCES
[1] Amtmann et al. 2004. Survey of cannabis use in patients with amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 21: 95-104.
[2] Raman et al. 2004. Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 5: 33-39.
[3] Weydt et al. 2005. Cannabinol delays symptom onset in SOD1 transgenic mice without affecting survival. Amyotrophic Lateral Sclerosis & Other Motor Neuron Disorders 6: 182-184.
[4] Bilsland et al. 2006. Increasing cannabinoid levels by pharmacological and genetic manipulation delay disease progression in SOD1 mice. The FASEB Journal 20: 1003-1005.
[5] Ibid.
[6] Raman et al. 2004. op.cit.
[7] Hampson et al. 1998. Cannabidiol and delta-9-tetrahydrocannabinol are neuroprotective antioxidants. Proceedings of the National Academy of Sciences 95: 8268-8273.
[8] Carter and Weydt. 2002. Cannabis: Old medicine with new promise for neurological disorders. Current Opinion in Investigational Drugs 3: 437-440.
[9] Abood et al. 2001. Activation of the CB1 cannabinoid receptor protects cultured mouse spinal neurons against excitotoxicity. Neuroscience Letters 309: 197-201.
[10] Carter and Rosen. 2001. Marijuana in the management of amyotrophic lateral sclerosis. The American Journal of Hospice and Palliative Care 18: 264-70.
[11] Carter et al. 2003. Drug therapy for amyotrophic lateral sclerosis: Where are we now? The Investigational Drugs Journal 6: 147-153.
source: [/url][url=?Group_ID=7004%5B/url%5D]http://www.norml.org...m?Group_ID=7004
Why choose Mayo Clinic
At Mayo Clinic, doctors who have training in neuromuscular conditions (neurologists) and several other specialists work closely as a team to care for people who have this condition. Doctors offer treatment and continuing care that can address your medical needs and improve your quality of life. Mayo Clinic offers you and your family many resources for support, information and education.
Mayo Clinic in Rochester, Minn., is ranked among the Best Hospitals for neurology and neurosurgery by U.S. News & World Report.
Read more about Lou Gehrig's disease at MayoClinic.com.